Caplin Steriles, the wholly owned subsidiary of Caplin Point Laboratories, announced that the US FDA has completed inspection
of its Sterile Injectable site at Gummidipoondi between 6 June and 14 June 2019. At the
end of this scheduled GMP inspection, there were only two observations. The
Company believes these to be of procedural in nature and the corrective and
preventive actions for these observations will be presented to the US FDA shortly. The
observations made were not repeat observations or related to data integrity.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
